3月10日,据CDE官网显示,山东新华制药提交的3类仿制药右酮洛芬氨丁三醇注射液的上市申请获受理。目前,该品种仅有2家药企成功获批并过评,若山东新华制药此次能顺利突围,将有望斩获国产第3家。截图来源:CDE官网一、同比增长超270%,市场潜力可期右酮洛芬氨丁三醇注射液原研为美纳里尼,作为阿片类镇痛药的辅助,用于成人不适合口服给药的急性中度至重度术后疼痛。最早于2002年获HMA批准上市, 尚未进入...
Source Link3月10日,据CDE官网显示,山东新华制药提交的3类仿制药右酮洛芬氨丁三醇注射液的上市申请获受理。目前,该品种仅有2家药企成功获批并过评,若山东新华制药此次能顺利突围,将有望斩获国产第3家。截图来源:CDE官网一、同比增长超270%,市场潜力可期右酮洛芬氨丁三醇注射液原研为美纳里尼,作为阿片类镇痛药的辅助,用于成人不适合口服给药的急性中度至重度术后疼痛。最早于2002年获HMA批准上市, 尚未进入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.